A link between malaria and Burkitt's lymphoma was first described more than 50 years ago, but how a parasitic infection could turn immune cells cancerous has remained a mystery. Now, researchers have demonstrated in mice that B cell DNA becomes vulnerable to cancer-causing mutations.
Adult patients with Burkitt lymphoma had excellent long-term survival rates—upwards of 90%—following treatment with low-intensity chemotherapy regimens, according to a new clinical trial finding.
High rates of freedom from disease, overall survival for standard-dose, with lower-dose EPOCH-R treatment.
A new study that tracked survival during the last decade of more than 2,200 adults with a highly aggressive form of lymphoma has found that medicine has made substantial progress in treating them successfully, with notable exceptions.
The first broad genetic landscape map of a Burkitt lymphoma tumor has identified 70 mutations, including several not previously associated with cancer and a new one that is unique to the disease.
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Encorafenib, Binimetinib Combination Receives FDA Approval for Mutation-Positive Melanoma
- Certain Risk Factors May Decrease Overall Survival in Pediatric B-NHL
- Oral Contraceptive Use May Not Be Associated With Increased Melanoma Risk
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|